Sino Biopharmaceutical logo

1177 - Sino Biopharmaceutical Share Price

HK$8.02 0.0  0.0%

Last Trade - 9:08am

Large Cap
Market Cap £15.13bn
Enterprise Value £15.78bn
Revenue £2.82bn
Position in Universe 88th / 5997
Unlock 1177 Revenue
Relative Strength (%)
1m -11.8%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -28.6%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
9,835 11,793 13,543 14,819 20,889 24,234 26,968 32,597 +19.8%
+49.8 +70.5 -19.1 +31.5 +19.9 -7.1 +17.4 +24.7
Balance Sheet
FINANCIAL BRIEF: : For the six months ended 30 June 2020, Sino Biopharmaceutical Limited revenues increased 1% to RMB12.65B. Net income decreased 16% to RMB1.21B. Revenues reflect Modernized Chinese Medicines and Chemical Medicines segment increase of 1% to RMB12.4B, Investment segment increase of 2% to RMB2.4M. Net income was offset by Investment segment loss increase from RMB103.2M to RMB531.6M.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for 1177
Graphical History


1177 Revenue Unlock 1177 Revenue

Net Income

1177 Net Income Unlock 1177 Revenue

Normalised EPS

1177 Normalised EPS Unlock 1177 Revenue

PE Ratio Range

1177 PE Ratio Range Unlock 1177 Revenue

Dividend Yield Range

1177 Dividend Yield Range Unlock 1177 Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
1177 EPS Forecasts Unlock 1177 Revenue
Profile Summary

Sino Biopharmaceutical Limited is an investment holding company principally engaged in the medicine products business. The Company operates through three business segments. The Modernized Chinese Medicines and Chemical Medicines segment is engaged in the manufacture, sales and distribution of modernized Chinese medicine products and western medicine products. The Investment segment is engaged in long term investments. The Others segment is engaged in the provision of research and development activities and services to third parties, as well as related healthcare and hospital business. The Company is also involved in the property holding, the sales of health food, the manufacture and optometry of optical glasses, as well as the retail and wholesale of optical and auditory products through its subsidiaries.

Last Annual December 31st, 2019
Last Interim June 30th, 2020
Incorporated February 2, 2000
Public Since December 8, 2003
No. of Shareholders: n/a
No. of Employees: 23,515
Sector Healthcare
Industry Pharmaceuticals
Index Hang Seng Composite , Hang Seng , Hang Seng Composite LargeCap & MidCap , Hang Seng Mainland 100 ,
Exchange Stock Exchange of Hong Kong Limited
Shares in Issue 18,872,627,230
Free Float (0.0%)
Eligible for
1177 Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for 1177
Upcoming Events for 1177
Tuesday 24th November, 2020 Estimate
Q3 2020 Sino Biopharmaceutical Ltd Earnings Release
Monday 29th March, 2021 Estimate
Q4 2020 Sino Biopharmaceutical Ltd Earnings Release
Frequently Asked Questions for Sino Biopharmaceutical
What is the Sino Biopharmaceutical share price?

As of 9:08am, shares in Sino Biopharmaceutical are trading at HK$8.02, giving the company a market capitalisation of £15.13bn. This share price information is delayed by 15 minutes.

How has the Sino Biopharmaceutical share price performed this year?

Shares in Sino Biopharmaceutical are currently trading at HK$8.02 and the price has moved by 7.8% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Sino Biopharmaceutical price has moved by 7.49% over the past year.

What are the analyst and broker recommendations for Sino Biopharmaceutical?

Of the analysts with advisory recommendations for Sino Biopharmaceutical, there are there are currently 10 "buy" , 4 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Sino Biopharmaceutical is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Sino Biopharmaceutical next release its financial results?

Sino Biopharmaceutical is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-06-30
What is the Sino Biopharmaceutical dividend yield?

The Sino Biopharmaceutical dividend yield is 0.79% based on the trailing twelve month period.

Does Sino Biopharmaceutical pay a dividend?

Last year, Sino Biopharmaceutical paid a total dividend of 0.05, and it currently has a trailing dividend yield of 0.79%. Looking ahead, Sino Biopharmaceutical has not announced an ex-dividend date yet.

When does Sino Biopharmaceutical next pay dividends?

Sino Biopharmaceutical has yet to annouce their ex-dividend date. The historic dividend yield on Sino Biopharmaceutical shares is currently 0.79%.

How do I buy Sino Biopharmaceutical shares?

To buy shares in Sino Biopharmaceutical you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Sino Biopharmaceutical?

Shares in Sino Biopharmaceutical are currently trading at HK$8.02, giving the company a market capitalisation of £15.13bn.

Where are Sino Biopharmaceutical shares listed? Where are Sino Biopharmaceutical shares listed?

Here are the trading details for Sino Biopharmaceutical:

Country of listing: Hong Kong
Exchange: HKG
Ticker Symbol: 1177
What kind of share is Sino Biopharmaceutical?

Based on an overall assessment of its quality, value and momentum, Sino Biopharmaceutical is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Sino Biopharmaceutical share price forecast 2020?

Shares in Sino Biopharmaceutical are currently priced at HK$8.02. At that level they are trading at 34.94% discount to the analyst consensus target price of 0.00.

Analysts covering Sino Biopharmaceutical currently have a consensus Earnings Per Share (EPS) forecast of 0.17 for the next financial year.

How can I tell whether the Sino Biopharmaceutical share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Sino Biopharmaceutical. Over the past six months, the relative strength of its shares against the market has been -12.61%. At the current price of HK$8.02, shares in Sino Biopharmaceutical are trading at -4.16% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Sino Biopharmaceutical PE Ratio?

The Sino Biopharmaceutical PE ratio based on its reported earnings over the past 12 months is 52.38. The shares are currently trading at HK$8.02.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of Sino Biopharmaceutical?

Sino Biopharmaceutical's management team is headed by:

Ping Tse - VCH
Cheung Ling Cheng - VCH
Dakui Li - NID
Chunling Li - VFN
Zhaocheng Tang - VPR
Zhengfei Lu - NID
Xiquan Zhang - SVP
Hong Lu - NID
Lu Fu Zhang - NID
Y Y Tse - CHM
Fajun Cai - VPR
Wenjun Shi - VPR
Jiayin Ma - CFO
Yi Li - CEO
Who are the major shareholders of Sino Biopharmaceutical?

Here are the top five shareholders of Sino Biopharmaceutical based on the size of their shareholding:

Tse (Eric S Y) Individual Investor
Percentage owned: 21.46% (4.05bn shares)
France Investment China 1 Group Ltd Corporation
Percentage owned: 12.08% (2.28bn shares)
Tse (Ping) Individual Investor
Percentage owned: 7.82% (1.48bn shares)
Cheng (Cheung Ling) Individual Investor
Percentage owned: 4.65% (878.2m shares)
The Vanguard Group, Inc. Investment Advisor/Hedge Fund
Percentage owned: 1.74% (327.9m shares)
Similar to 1177
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.